سعر اسباراجينيز-ميداك 10000 وحدة دولية فيال 2026

Asparaginase-medac 10,000 IU, single vial of powder for solution for injection (medac GmbH, Germany; imported by the Egyptian Pharmaceutical Trading Company): E. coli-derived L-asparaginase, an antineoplastic enzyme used in multi-agent chemotherapy for acute lymphoblastic leukaemia.

• Component of combination antineoplastic therapy for acute lymphoblastic leukaemia (ALL) in children and adults.Population: Children and adults (Polish SmPC)Rejestr Produktów Leczniczych (URPL, Poland)
• Component of combination therapy for non-Hodgkin lymphoma in children.Population: Children (Polish SmPC)Rejestr Produktów Leczniczych (URPL, Poland)

• Very common: fatigue. Common: fever. Uncommon: rash, urticaria, coagulation and fibrinolysis disorders, nausea, vomiting, anorexia.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)
• Rare: dyspnoea up to anaphylactic shock, hyperpyrexia, pancreatitis, reduced glucose tolerance, liver dysfunction and raised liver enzymes, thromboembolism, raised urea and uric acid, lethargy, somnolence, confusion. Very rare: haemorrhagic pancreatitis, ketoacidosis, hypoalbuminaemia, seizures, haemorrhage. Isolated cases: toxic epidermal necrolysis, pancreatic pseudocysts, cholestasis/jaundice, hepatocyte necrosis, haemolytic anaemia, transient hypothyroidism.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)

• Hypersensitivity to asparaginase.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)
• Current or previous pancreatitis.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)
• History of allergic reactions to E. coli-derived asparaginase.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)

• Hypersensitivity reactions up to anaphylactic shock may occur; a skin or intradermal test and an intravenous test dose should precede treatment, with resuscitation facilities available.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)
• Pancreatitis may occur: monitor serum amylase frequently and stop treatment if pancreatitis develops; pancreatic pseudocysts may appear months later, so monitoring (e.g. ultrasound) for about 4 months after treatment is advised.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)
• Hyperglycaemia may occur; monitor blood and urine glucose. Uric acid may rise. Coagulation disorders and liver dysfunction may occur.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)

• VincristineGiving vincristine immediately before or together with asparaginase increases toxicity and the risk of anaphylactic reactions.Rejestr Produktów Leczniczych (URPL, Poland)
• PrednisoloneConcomitant prednisolone increases the risk of coagulation disorders.Rejestr Produktów Leczniczych (URPL, Poland)
• Methotrexate, cytarabineGiven before asparaginase they may act synergistically; given after asparaginase their effect may be antagonised.Rejestr Produktów Leczniczych (URPL, Poland)

• Must not be used during pregnancy unless clearly necessary; effective contraception is required during treatment and for at least 3 months afterwards.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)
• Breast-feeding must be discontinued during treatment.International label, same product · Rejestr Produktów Leczniczych (URPL, Poland)

• Asparaginase (L-asparaginase from Escherichia coli): Hydrolyses L-asparagine to L-aspartic acid and ammonia; leukaemic cells with low asparagine synthetase activity are deprived of exogenous asparagine, which inhibits protein synthesis and cell proliferation.